Mirum Pharmaceuticals logo

Mirum PharmaceuticalsNASDAQ: MIRM

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

18 July 2019

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$1.93 B
-9%vs. 3y high
80%vs. sector
-vs. 3y high
-vs. sector
-57%vs. 3y high
91%vs. sector
-81%vs. 3y high
68%vs. sector

Price

after hours | 26 min ago
$40.45+$0.05(+0.12%)

Dividend

No data over the past 3 years
$77.88 M$82.01 M
$77.88 M-$24.64 M

Analysts recommendations

Institutional Ownership

MIRM Latest News

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
businesswire.com04 November 2024 Sentiment: -

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024.

Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
zacks.com06 September 2024 Sentiment: POSITIVE

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?

Mirum (MIRM) Banks on Livmarli, Overdependence a Concern
zacks.com19 August 2024 Sentiment: POSITIVE

Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further.

Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top
zacks.com08 August 2024 Sentiment: POSITIVE

Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
zacks.com07 August 2024 Sentiment: POSITIVE

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.92 per share a year ago.

Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?
zacks.com29 July 2024 Sentiment: POSITIVE

Mirum Pharmaceuticals (MIRM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
seekingalpha.com17 July 2024 Sentiment: POSITIVE

Mirum Pharmaceuticals develops therapies for rare liver diseases, focusing on bile acid regulation. Key products include Livmarli, Cholbam, and Chenodal, with Chenodal recently completing Phase 3 trials for CTX. MIRM's pipeline also has Volixibat in Phase 2b trials for PSC and PBC.

Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
zacks.com09 July 2024 Sentiment: POSITIVE

The European Commission approves Mirum's (MIRM) Livmarli for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
zacks.com18 June 2024 Sentiment: POSITIVE

Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Mirum (MIRM) Soars on Interim Data From Liver Disease Studies
zacks.com18 June 2024 Sentiment: POSITIVE

Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.

  • 1(current)
  • 2

What type of business is Mirum Pharmaceuticals?

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

What sector is Mirum Pharmaceuticals in?

Mirum Pharmaceuticals is in the Healthcare sector

What industry is Mirum Pharmaceuticals in?

Mirum Pharmaceuticals is in the Biotechnology industry

What country is Mirum Pharmaceuticals from?

Mirum Pharmaceuticals is headquartered in United States

When did Mirum Pharmaceuticals go public?

Mirum Pharmaceuticals initial public offering (IPO) was on 18 July 2019

What is Mirum Pharmaceuticals website?

https://www.mirumpharma.com

Is Mirum Pharmaceuticals in the S&P 500?

No, Mirum Pharmaceuticals is not included in the S&P 500 index

Is Mirum Pharmaceuticals in the NASDAQ 100?

No, Mirum Pharmaceuticals is not included in the NASDAQ 100 index

Is Mirum Pharmaceuticals in the Dow Jones?

No, Mirum Pharmaceuticals is not included in the Dow Jones index

When was Mirum Pharmaceuticals the previous earnings report?

No data

When does Mirum Pharmaceuticals earnings report?

Next earnings report date is not announced yet